PAS
VRDN icon

Point72 Asia (Singapore)’s Viridian Therapeutics VRDN Stock Holding History

Point72 Asia (Singapore)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44
Closed -$617 – 1268
2025
Q2 		$617 Buy
+44
New +$597 ﹤0.01% 833
2024
Q4 		– Sell
-6,543
Closed -$149K – 1248
2024
Q3 		$149K Buy
+6,543
New +$107K 0.03% 441

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Point72 Asia (Singapore)'s VRDN Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Viridian Therapeutics (VRDN) in Q3 2025, closing a stake of 44 shares — an estimated $617 sold.

Point72 Asia (Singapore) first reported a position in VRDN in Q3 2024 and held it in 2 quarters. The position peaked at $149K in Q3 2024. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

  • Point72 Asia (Singapore) reported no remaining Viridian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 44 Viridian Therapeutics shares in Q3 2025, an estimated $617.
  • Point72 Asia (Singapore) first reported a position in Viridian Therapeutics in Q3 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Viridian Therapeutics position peaked at $149K in Q3 2024.
  • 169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.